

Drug Monograph

Drug Name: **Ajovy[®] (fremanezumab-vfrm) Autoinjector**
Drug Class: **Calcitonin Gene-Related Peptide Receptors**
Prepared For: MO HealthNet
Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Ajovy is now available as a 225 mg/1.5 mL single-dose, prefilled autoinjector

Manufacturer: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454

Indications: Ajovy is indicated for the preventive treatment of migraine in adults.

Costs: \$603 per auto injector Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Jennifer Anderson PharmD, BCPS
Date: August 17, 2020